Fig. 5
From: AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
The enhanced therapeutic effect of AT-101 on gefitinib in NSCLC cells with the T790M mutation through inhibition of antiapoptotic proteins and molecules of EGFR pathway. PC-9-GR and H1975 cells were treated with 5 μM AT-101, 1μM gefitinib or a combination as indicated for 12 hours. Western blot analysis was performed to detect the expression of p-EGFR, EGFR, p-Akt, Akt, p-Erk, Erk, Bcl-2, Bcl-xl, Mcl-1, and cleaved caspase 3. β-actin was used as the loading control